Gen3009 (Anti-CD37)

Synonyms: Ivicentamab, DuoHexaBody-CD37

For research use only. Not for use in humans.

Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.

Gen3009 (Anti-CD37)

Purity & Quality Control

Gen3009 (Anti-CD37) Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.

Product Details

CAS No. 2364496-42-2
Source CHO
Storage
(From the date of receipt)
-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.